Market Summary
USD27.62+1.82
Market Closed7.05%
GH Stock Price
GH RSI Chart
GH Valuation
GH Price/Sales (Trailing)
GH Profitability
GH Fundamentals
GH Revenue
GH Earnings
Price Action
52 Week Range
20.6762.75
(Low)(High)
Last 7 days
0.7%
Last 30 days
-27.7%
Last 90 days
-23.9%
Trailing 12 Months
-44.3%
GH Financial Health
GH Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for GH
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Bell Michael Brian | sold (taxes) | -12,609 | 29.53 | -427 | chief financial officer |
2023-09-15 | Bell Michael Brian | acquired | - | - | 1,233 | chief financial officer |
2023-09-15 | POTTER MYRTLE S | acquired | - | - | 69.00 | - |
2023-09-12 | Kalia Kumud | sold | -69,253 | 32.59 | -2,125 | chief information officer |
2023-09-09 | Kalia Kumud | sold (taxes) | -76,308 | 33.72 | -2,263 | chief information officer |
2023-09-09 | Saia John G. | sold (taxes) | -10,183 | 33.72 | -302 | chief legal officer |
2023-09-09 | Kalia Kumud | acquired | - | - | 6,544 | chief information officer |
2023-09-09 | Chudova Darya | acquired | - | - | 2,908 | chief technology officer |
2023-09-09 | Chudova Darya | sold (taxes) | -33,922 | 33.72 | -1,006 | chief technology officer |
2023-09-09 | Merrill Amelia | sold (taxes) | -12,240 | 33.72 | -363 | svp, people |
Which funds bought or sold GH recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | reduced | -21.56 | 120,682 | 2,703,770 | 0.02% |
2023-09-21 | Baystate Wealth Management LLC | new | - | 2,864 | 2,864 | -% |
2023-09-20 | BARCLAYS PLC | added | 33.08 | 3,691,000 | 7,264,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 149 | 430 | -% |
2023-09-07 | Triatomic Management LP | reduced | -42.97 | -106,088 | 716,000 | 0.73% |
2023-09-06 | Deep Track Capital, LP | new | - | 53,700,000 | 53,700,000 | 2.49% |
2023-08-24 | Adalta Capital Management LLC | reduced | -0.85 | 987,000 | 2,906,000 | 1.94% |
2023-08-23 | Stonebridge Capital Advisors LLC | new | - | 1,969 | 1,969 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 118 | 799,796 | 1,142,020 | 0.01% |
2023-08-22 | COMERICA BANK | new | - | 64,000 | 64,000 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Guardant Health
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Mar 10, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 14, 2023 | viking global investors lp | 4.0% | 4,107,644 | SC 13G/A | |
| Feb 13, 2023 | capital international investors | 7.7% | 7,879,355 | SC 13G | |
| Feb 13, 2023 | capital research global investors | 2.0% | 2,001,782 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.83% | 9,040,240 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 5.4% | 5,495,293 | SC 13G | |
| Mar 09, 2022 | blackrock inc. | 4.9% | 4,961,865 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 7.8% | 7,927,702 | SC 13G | |
| Feb 10, 2022 | fmr llc | - | 0 | SC 13G/A |
Recent SEC filings of Guardant Health
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 13, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 8-K | Current Report | |
| Sep 06, 2023 | 4 | Insider Trading |
Peers (Alternatives to Guardant Health)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HCA | 67.5B | 61.9B | -10.91% | 34.15% | 11.69 | 1.09 | 3.02% | -11.37% |
LH | 18.2B | 14.1B | -3.48% | -0.57% | 21.87 | 1.29 | -5.68% | -58.27% |
DGX | 13.8B | 9.5B | -6.83% | 1.44% | 17.41 | 1.46 | -10.34% | -46.50% |
| MID-CAP | ||||||||
UHS | 8.7B | 13.8B | -6.62% | 41.44% | 12.58 | 0.63 | 5.76% | -10.75% |
EHC | 6.7B | 4.6B | -4.11% | 45.48% | 21.27 | 1.46 | 9.56% | -4.24% |
ENSG | 5.2B | 3.4B | -5.62% | 16.47% | 21.63 | 1.54 | 20.66% | 17.86% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
GH | 3.2B | 510.2M | -27.73% | -44.30% | -6.39 | 6.37 | 25.00% | 4.56% |
AMN | 3.1B | 4.4B | -5.01% | -18.52% | 9.85 | 0.72 | -16.06% | -30.43% |
AMED | 3.0B | 2.2B | -0.58% | -8.34% | 1.3K | 1.36 | 0.61% | -98.34% |
| SMALL-CAP | ||||||||
RDNT | 1.9B | 1.5B | -9.98% | 59.13% | -149.89 | 1.27 | 12.20% | -155.34% |
BKD | 737.9M | 3.0B | -6.00% | -10.91% | -7.16 | 0.25 | 11.66% | -12.20% |
ENZ | 68.5M | 71.0M | -13.21% | -34.29% | -1.5 | 0.97 | -36.38% | -594.74% |
XGN | 42.7M | 52.9M | 1.20% | -5.95% | -1.21 | 0.81 | 23.27% | 10.26% |
PMD | 21.3M | 23.6M | -14.52% | -42.66% | -11.24 | 0.9 | -9.62% | -60.46% |
Guardant Health News
Returns for GH
Cumulative Returns on GH
-37.2%
3-Year Cumulative Returns
Risks for GH
What is the probability of a big loss on GH?
96.9%
Probability that Guardant Health stock will be more than 20% underwater in next one year
85.4%
Probability that Guardant Health stock will be more than 30% underwater in next one year.
60%
Probability that Guardant Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does GH drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.
Drawdowns
Financials for Guardant Health
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 5.8% | 510,159,000 | 482,153,000 | 449,538,000 | 430,755,000 | 408,130,000 | 391,087,000 | 373,653,000 | 343,861,000 | 323,651,000 | 297,885,000 | 286,730,000 | 271,311,000 | 257,590,000 | 245,230,000 | 214,375,000 | 184,351,000 | 145,195,000 | 110,602,000 | 90,639,000 | 77,768,000 | 67,208,000 |
| S&GA Expenses | -0.8% | 308,959,000 | 311,519,000 | 299,828,000 | 278,004,000 | 247,862,000 | 221,975,000 | 191,881,000 | 163,570,000 | 138,437,000 | 115,736,000 | 106,513,000 | 97,512,000 | 91,219,000 | 85,643,000 | 78,335,000 | 73,162,000 | 67,824,000 | 59,960,000 | 53,465,000 | 45,907,000 | 40,251,000 |
| R&D Expenses | 1.3% | 390,082,000 | 385,178,000 | 373,807,000 | 340,250,000 | 311,201,000 | 289,470,000 | 263,221,000 | 230,482,000 | 195,759,000 | 168,354,000 | 149,862,000 | 135,455,000 | 123,779,000 | 106,992,000 | 86,292,000 | 77,069,000 | 66,753,000 | 58,775,000 | 50,714,000 | 42,182,000 | 35,175,000 |
| EBITDA | 100.0% | - | -621,807,000 | -614,910,000 | -551,958,000 | -501,772,000 | -374,508,000 | -359,622,000 | -378,569,000 | -344,577,000 | -298,166,000 | -225,073,000 | -160,460,000 | -103,279,000 | -66,952,000 | -57,131,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -1.29 | -1.37 | -1.28 | -1.23 | -0.96 | -0.96 | -1.10 | -1.06 | -1.00 | -0.78 | -0.59 | -0.40 | -0.27 | -0.27 | - | - | - | - | - | - |
| Interest Expenses | 0% | 2,577,000 | 2,577,000 | 2,577,000 | 2,576,000 | 2,576,000 | 2,575,000 | 2,577,000 | 6,670,000 | 6,034,000 | 5,400,000 | 4,766,000 | 351,000 | 623,000 | 900,000 | 1,181,000 | 1,159,000 | 1,183,000 | 1,213,000 | 1,251,000 | 1,256,000 | 1,255,000 |
| Earnings Before Taxes | 23.6% | -506,779,000 | -663,490,000 | -653,449,000 | -586,417,000 | -531,968,000 | -400,474,000 | -384,470,000 | -404,952,000 | -369,124,000 | -321,337,000 | -245,904,000 | -175,721,000 | -117,411,000 | -80,213,000 | -69,723,000 | -72,361,000 | -82,577,000 | -91,706,000 | -84,225,000 | -74,041,000 | -79,123,000 |
| EBT Margin | 100.0% | - | -1.38 | -1.45 | -1.36 | -1.30 | -1.02 | -1.03 | -1.18 | -1.14 | -1.08 | -0.86 | -0.65 | -0.46 | -0.33 | -0.33 | - | - | - | - | - | - |
| Net Income | 23.6% | -508,232,000 | -664,893,000 | -654,588,000 | -586,965,000 | -532,497,000 | -400,640,000 | -384,770,000 | -405,504,000 | -369,648,000 | -321,812,000 | -246,283,000 | -175,348,000 | -116,768,000 | -78,329,000 | -67,851,000 | -71,013,000 | -81,431,000 | -91,770,000 | -84,263,000 | -74,051,000 | -79,133,000 |
| Net Income Margin | 100.0% | - | -1.38 | -1.46 | -1.36 | -1.30 | -1.02 | -1.03 | -1.18 | -1.14 | -1.08 | -0.86 | -0.68 | -0.48 | -0.35 | -0.35 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -417,570,000 | -386,924,000 | -387,787,000 | -363,195,000 | -309,494,000 | -284,052,000 | -248,944,000 | -191,493,000 | -143,097,000 | -140,100,000 | -111,026,000 | -97,712,000 | -81,723,000 | -65,851,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2017Q4 |
| Assets | 21.7% | 1,840 | 1,512 | 1,610 | 1,702 | 1,854 | 2,130 | 2,204 | 2,226 | 2,292 | 2,347 | 2,272 | 1,262 | 1,278 | 948 | 963 | 948 | 940 | 579 | 587 | 345 | 343 |
| Current Assets | 26.5% | 1,398 | 1,104 | 1,192 | 1,131 | 1,037 | 1,113 | 1,114 | 1,593 | 1,891 | 2,033 | 1,888 | 1,087 | 1,010 | 607 | 597 | 583 | 604 | 512 | 469 | 297 | 243 |
| Cash Equivalents | 21.2% | 271 | 224 | 142 | 158 | 215 | 574 | 492 | 832 | 939 | 869 | 833 | 143 | 165 | 152 | 143 | 147 | 175 | 154 | 141 | 114 | 73.00 |
| Inventory | 30.2% | 61.00 | 46.00 | 52.00 | 63.00 | 60.00 | 37.00 | 31.00 | 25.00 | 26.00 | 29.00 | 23.00 | 28.00 | 20.00 | 25.00 | 15.00 | 15.00 | 14.00 | 10.00 | 9.00 | 7.00 | 7.00 |
| Net PPE | -4.6% | 156 | 163 | 168 | 168 | 163 | 151 | 124 | 106 | 90.00 | 72.00 | 63.00 | 62.00 | 57.00 | 47.00 | 44.00 | 41.00 | 35.00 | 31.00 | 31.00 | 30.00 | 16.00 |
| Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | - | - | - | - | - |
| Liabilities | -0.6% | 1,547 | 1,556 | 1,550 | 1,535 | 1,535 | 1,597 | 1,559 | 1,457 | 1,444 | 1,440 | 916 | 114 | 113 | 118 | 115 | 86.00 | 78.00 | 65.00 | 62.00 | 47.00 | 34.00 |
| Current Liabilities | -1.6% | 201 | 204 | 193 | 175 | 168 | 229 | 195 | 102 | 97.00 | 96.00 | 67.00 | 72.00 | 70.00 | 82.00 | 73.00 | 68.00 | 57.00 | 48.00 | 47.00 | 32.00 | 20.00 |
| Shareholder's Equity | 757.1% | 293 | -44.55 | 60.00 | 167 | 319 | 533 | 645 | 709 | 788 | 847 | 1,298 | 1,092 | 1,115 | 785 | 798 | 815 | 815 | 468 | 483 | 255 | 309 |
| Retained Earnings | -4.1% | -1,868 | -1,795 | -1,662 | -1,522 | -1,360 | -1,131 | -1,007 | -916 | -809 | -711 | -606 | -512 | -435 | -380 | -352 | -327 | -314 | -303 | -280 | -255 | -195 |
| Additional Paid-In Capital | 23.0% | 2,170 | 1,764 | 1,742 | 1,716 | 1,704 | 1,682 | 1,658 | 1,627 | 1,597 | 1,558 | 1,902 | 1,601 | 1,544 | 1,158 | 1,150 | 1,142 | 1,129 | 771 | 764 | 11.00 | 5.00 |
| Shares Outstanding | 14.6% | 118 | 103 | 103 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 100 | 100 | 96.00 | 94.00 | 94.00 | 93.00 | 89.00 | 86.00 | 30.00 | 12.00 | 13.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 5.0% | -337 | -355 | -309 | -295 | -270 | -221 | -209 | -191 | -146 | -106 | -103 | -75.05 | -65.64 | -56.11 | -47.13 | -43.33 | -66.72 | -69.93 | -72.18 | -63.64 | -55.45 |
| Share Based Compensation | -3.5% | 89.00 | 92.00 | 95.00 | 98.00 | 112 | 121 | 151 | 181 | 202 | 193 | 144 | 92.00 | 43.00 | 20.00 | 17.00 | 14.00 | 11.00 | 9.00 | 7.00 | 6.00 | 5.00 |
| Cashflow From Investing | -85.7% | 28.00 | 196 | 150 | -187 | -276 | -76.22 | -63.15 | -94.14 | -61.40 | -514 | -617 | -296 | -317 | -312 | -317 | -538 | -478 | -146 | -153 | -51.16 | -100 |
| Cashflow From Financing | 292.7% | 366 | -189 | -189 | -187 | -173 | 3.00 | -66.82 | 976 | 982 | 1,339 | 1,410 | 367 | 373 | 366 | 367 | 615 | 609 | 294 | 293 | 43.00 | 56.00 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
GH Income Statement
2023-06-30Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Precision oncology testing | $ 125,244 | $ 92,062 | $ 238,637 | $ 176,198 |
| Development services and other | 11,906 | 17,082 | 27,227 | 29,045 |
| Total revenue | 137,150 | 109,144 | 265,864 | 205,243 |
| Costs and operating expenses: | ||||
| Cost of precision oncology testing | 49,357 | 34,375 | 94,463 | 65,059 |
| Cost of development services and other | 4,491 | 2,352 | 12,458 | 3,649 |
| Research and development expense | 90,359 | 85,455 | 183,487 | 167,212 |
| Sales and marketing expense | 71,043 | 73,603 | 147,166 | 138,035 |
| General and administrative expense | 41,516 | 43,680 | 81,961 | 84,947 |
| Total costs and operating expenses | 256,766 | 239,465 | 519,535 | 458,902 |
| Loss from operations | (119,616) | (130,321) | (253,671) | (253,659) |
| Interest income | 6,727 | 1,387 | 9,787 | 2,165 |
| Interest expense | (645) | (645) | (1,289) | (1,289) |
| Other income (expense), net | 41,259 | 378 | 39,605 | 330 |
| Fair value adjustments of noncontrolling interest liability | 0 | (99,785) | 0 | (99,785) |
| Loss before provision for income taxes | (72,275) | (228,986) | (205,568) | (352,238) |
| Provision for income taxes | 496 | 446 | 736 | 422 |
| Net loss | $ (72,771) | $ (229,432) | $ (206,304) | $ (352,660) |
| Net loss per share, basic (in usd per share) | $ (0.67) | $ (2.25) | $ (1.95) | $ (3.46) |
| Net loss per share, diluted (in usd per share) | $ (0.67) | $ (2.25) | $ (1.95) | $ (3.46) |
| Weighted-average shares used in computing net loss per share , basic (in shares) | 108,808 | 102,047 | 105,752 | 101,950 |
| Weighted-average shares used in computing net loss per share, diluted (in shares) | 108,808 | 102,047 | 105,752 | 101,950 |
GH Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 271,073 | $ 141,647 |
| Short-term marketable debt securities | 953,776 | 869,584 |
| Accounts receivable, net | 86,468 | 97,256 |
| Inventory, net | 60,529 | 51,598 |
| Prepaid expenses and other current assets, net | 25,809 | 31,509 |
| Total current assets | 1,397,655 | 1,191,594 |
| Property and equipment, net | 155,741 | 167,920 |
| Right-of-use assets, net | 165,273 | 174,001 |
| Intangible assets, net | 10,361 | 11,727 |
| Goodwill | 3,290 | 3,290 |
| Other assets, net | 107,697 | 61,453 |
| Total Assets | 1,840,017 | 1,609,985 |
| Current liabilities: | ||
| Accounts payable and accrued liabilities | 188,696 | 175,817 |
| Deferred revenue | 12,237 | 17,403 |
| Total current liabilities | 200,933 | 193,220 |
| Convertible senior notes, net | 1,138,678 | 1,137,391 |
| Long-term operating lease liabilities | 198,230 | 210,015 |
| Other long-term liabilities | 9,450 | 9,179 |
| Total Liabilities | 1,547,291 | 1,549,805 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2023, and December 31, 2022; 117,662,134 and 102,619,383 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively | 1 | 1 |
| Additional paid-in capital | 2,169,911 | 1,742,114 |
| Accumulated other comprehensive loss | (8,469) | (19,522) |
| Accumulated deficit | (1,868,717) | (1,662,413) |
| Total Stockholders’ Equity | 292,726 | 60,180 |
| Total Liabilities and Stockholders’ Equity | $ 1,840,017 | $ 1,609,985 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.